PetMed Express (PETS) Aandelenoverzicht
PetMed Express, Inc. is samen met haar dochterondernemingen actief als dierenapotheek in de Verenigde Staten. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 2/6 |
| Toekomstige groei | 3/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
PETS Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
PetMed Express, Inc. Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$1.83 |
| 52 Week Hoogtepunt | US$4.10 |
| 52 Week Laag | US$1.57 |
| Bèta | 0.77 |
| 1 maand verandering | -13.68% |
| 3 maanden verandering | -20.78% |
| 1 Jaar Verandering | -44.04% |
| 3 jaar verandering | -86.78% |
| 5 jaar verandering | -94.25% |
| Verandering sinds IPO | 46.40% |
Recent nieuws en updates
PETS: Rural King Partnership And Board Review Will Support Future Upside
Analysts have adjusted their price target for PetMed Express to reflect updated views on revenue growth, profit margins, and a future P/E of 12.41. This has led to a revised valuation that aligns more closely with their current earnings expectations for the stock.PETS: Rural King White Label Pharmacy Will Support Future Margin Upside
Analysts have kept their price target on PetMed Express effectively unchanged at about $2.15, reflecting only very small tweaks to inputs such as discount rate, expected revenue trend, profit margin and future P/E assumptions. What's in the News PetMed Express announced a partnership with Rural King to launch a pet pharmacy service across Rural King retail stores and digital platforms, offering prescription medications, preventatives and other pet health products.PetMed Express: High-Risk Turnaround, Hidden Assets, Activism
Summary PetMed Express’ current valuation suggests investors are pricing in a significant deterioration in the franchise. Execution risk is substantial. The assets provide downside support - although continued operating losses will reduce that support. Ultimately, the investment case depends less on asset values and more on on whether management can stabilize revenue and translate operational improvements into earnings. PETS is more of an asset-backed special situation than an operational turnaround. Read the full article on Seeking AlphaRecent updates
PETS: Rural King Partnership And Board Review Will Support Future Upside
Analysts have adjusted their price target for PetMed Express to reflect updated views on revenue growth, profit margins, and a future P/E of 12.41. This has led to a revised valuation that aligns more closely with their current earnings expectations for the stock.PETS: Rural King White Label Pharmacy Will Support Future Margin Upside
Analysts have kept their price target on PetMed Express effectively unchanged at about $2.15, reflecting only very small tweaks to inputs such as discount rate, expected revenue trend, profit margin and future P/E assumptions. What's in the News PetMed Express announced a partnership with Rural King to launch a pet pharmacy service across Rural King retail stores and digital platforms, offering prescription medications, preventatives and other pet health products.PetMed Express: High-Risk Turnaround, Hidden Assets, Activism
Summary PetMed Express’ current valuation suggests investors are pricing in a significant deterioration in the franchise. Execution risk is substantial. The assets provide downside support - although continued operating losses will reduce that support. Ultimately, the investment case depends less on asset values and more on on whether management can stabilize revenue and translate operational improvements into earnings. PETS is more of an asset-backed special situation than an operational turnaround. Read the full article on Seeking AlphaPETS: Rural King Partnership Will Shape Future Margins And Earnings Outlook
Analysts have slightly reduced their price target on PetMed Express, attributing the change to a marginally lower discount rate and a modest increase in the assumed future P/E multiple as the main factors behind the revised outlook. What's in the News PetMed Express announced a partnership with Rural King to launch a new pet pharmacy offering across Rural King’s retail stores and digital platforms, focusing on prescription medications, preventatives and broader pet health products (Key Developments).PETS: Rural King Partnership Will Shape Future Margins And Earnings Multiple
Analysts have trimmed their price target on PetMed Express to reflect a fair value update from $3.00 to $2.15 as they incorporate more moderate expectations for revenue contraction, profit margins, and a higher future P/E multiple into their models. What's in the News PetMed Express announced a partnership with Rural King to launch a new pet pharmacy offering across Rural King retail stores and digital platforms, expanding access to prescription medications, preventatives and pet health products for Rural King customers (Key Developments).Getting In Cheap On PetMed Express, Inc. (NASDAQ:PETS) Is Unlikely
It's not a stretch to say that PetMed Express, Inc.'s ( NASDAQ:PETS ) price-to-sales (or "P/S") ratio of 0.3x right now...Some Confidence Is Lacking In PetMed Express, Inc. (NASDAQ:PETS) As Shares Slide 26%
To the annoyance of some shareholders, PetMed Express, Inc. ( NASDAQ:PETS ) shares are down a considerable 26% in the...
Cost Cuts And Digital Upgrades Will Strain Future Margins
Optimism regarding savings from PetCareRx integration could jeopardize future profitability if anticipated savings do not materialize.PetMed Express: Dip Or Rip, A Buy After Earnings
Summary PetMed Express stock could surge or sink after this week's quarterly earnings release, but don't read too much into this near-term event. A disappointing earnings release won't necessarily shatter the bull case, and could, in fact, push this stock back down to "back up the truck" price levels. Conversely, even if PETS rallies on strong results, this may not capture all of the potential long-term upside. Even if it takes time to take shape, improvements in PetMed's operating performance could ultimately send the stock back to prices north of $15 per share. Read the full article on Seeking AlphaWe Think PetMed Express (NASDAQ:PETS) Can Easily Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Some PetMed Express, Inc. (NASDAQ:PETS) Shareholders Look For Exit As Shares Take 28% Pounding
PetMed Express, Inc. ( NASDAQ:PETS ) shares have retraced a considerable 28% in the last month, reversing a fair amount...PetMed Express: Why (And Why Not) The Rebound Could Continue
Summary PetMed Express (PETS) surged 35.8% on Nov. 7, following the online pet pharmacy's latest quarterly earnings release. Despite the massive post-earnings surge, further upside may lie ahead, if the turnaround continues. PetMed's management team is implementing a strategy change, not just cost-cutting measures, to continue improving the company's fiscal performance. Although many risks and uncertainties remain, given the outsized impact further improvements could have on the PETS stock price, at the very least add it to your watchlist. Read the full article on Seeking AlphaOptimistic Investors Push PetMed Express, Inc. (NASDAQ:PETS) Shares Up 28% But Growth Is Lacking
PetMed Express, Inc. ( NASDAQ:PETS ) shares have had a really impressive month, gaining 28% after a shaky period...PetMed Express, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
There's been a notable change in appetite for PetMed Express, Inc. ( NASDAQ:PETS ) shares in the week since its...PetMed Express, Inc. (NASDAQ:PETS) Just Reported And Analysts Have Been Cutting Their Estimates
PetMed Express, Inc. ( NASDAQ:PETS ) last week reported its latest annual results, which makes it a good time for...PetMed Express, Inc.'s (NASDAQ:PETS) Intrinsic Value Is Potentially 69% Above Its Share Price
Key Insights Using the Dividend Discount Model, PetMed Express fair value estimate is US$7.95 Current share price of...A Look At The Fair Value Of PetMed Express, Inc. (NASDAQ:PETS)
Key Insights PetMed Express' estimated fair value is US$11.85 based on 2 Stage Free Cash Flow to Equity Current share...PetMed Express (NASDAQ:PETS) Is Paying Out A Dividend Of $0.30
The board of PetMed Express, Inc. ( NASDAQ:PETS ) has announced that it will pay a dividend of $0.30 per share on the...Rendement voor aandeelhouders
| PETS | US Specialty Retail | US Markt | |
|---|---|---|---|
| 7D | 1.7% | -2.7% | -2.3% |
| 1Y | -44.0% | 4.6% | 21.2% |
Rendement versus industrie: PETS presteerde slechter dan de US Specialty Retail -sector, die het afgelopen jaar een rendement van 4.6 % opleverde.
Rendement versus markt: PETS presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 21.2 % opleverde.
Prijsvolatiliteit
| PETS volatility | |
|---|---|
| PETS Average Weekly Movement | 7.1% |
| Specialty Retail Industry Average Movement | 7.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: PETS heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend vergeleken met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit van PETS is het afgelopen jaar gedaald van 14% naar 7%.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1996 | 189 | Leslie C. Campbell | www.1800petmeds.com |
PetMed Express, Inc. is samen met haar dochterondernemingen actief als dierenapotheek in de Verenigde Staten. Het bedrijf verkoopt medicijnen, gezondheidsproducten en andere benodigdheden voor honden, katten en paarden, al dan niet op recept. Het bedrijf biedt medicijnen en benodigdheden zonder recept, zoals vlooien- en tekenbestrijdingsproducten, bot- en gewrichtsverzorgingsproducten, vitaminen, traktaties, voedingssupplementen, hygiëneproducten en huishoudelijke benodigdheden voor huisdieren; en medicijnen op recept, waaronder medicijnen tegen hartworm, vlooien- en tekenpreventie, artritis, dermatitis, schildklier, diabetes, pijnmedicatie, hart/bloeddruk en andere speciale medicijnen, evenals generieke substituten.
PetMed Express, Inc. Samenvatting
| PETS fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$38.48m |
| Inkomsten(TTM) | -US$57.29m |
| Inkomsten(TTM) | US$179.02m |
Is PETS overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| PETS resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$179.02m |
| Kosten van inkomsten | US$128.81m |
| Brutowinst | US$50.22m |
| Overige uitgaven | US$107.50m |
| Inkomsten | -US$57.29m |
Laatst gerapporteerde inkomsten
Mar 31, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -2.72 |
| Brutomarge | 28.05% |
| Nettowinstmarge | -32.00% |
| Schuld/Eigen Vermogen Verhouding | 0% |
Hoe presteerde PETS op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/24 00:52 |
| Aandelenkoers aan het einde van de dag | 2026/06/24 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
PetMed Express, Inc. wordt gevolgd door 15 analisten. 1 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Erin Wilson Wright | BofA Global Research |
| Kristine Koerber | Citizens JMP Securities, LLC |
| David Westenberg | CL King & Associates, Inc. |